5 hours Ago By ABMN Staff
Guardian Investment Management trimmed its position in Johnson & Johnson ( NYSE:JNJ – Free Report ) by 2.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 19,472 shares of the company’s stock after selling 550 shares during the quarter.
Johnson & Johnson comprises 1.9% of Guardian Investment Management’s holdings, making the stock its 14th largest position. Guardian Investment Management’s holdings in Johnson & Johnson were worth $2,816,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. International Assets Investment Management LLC lifted its stake in Johnson & Johnson by 20,130.0% during the 3rd quarter.
International Assets Investment Management LLC now owns 3,454,473 shares of the company’s stock valued at $559,832,000 after acquiring an additional 3,437,397 shares during the period. Marshall Wace LLP lifted its position in Johnson & Johnson by 506.9% during the second quarter.
Marshall Wace LLP now owns 3,884,962 shares of the company’s stock valued at $567,826,000 after purchasing an additional 3,244,862 shares during the period. Janus Henderson Group PLC boosted its holdings in Johnson & Johnson by 228.1% in the third quarter.
Janus Henderson Group PLC now owns 3,389,361 shares of the company’s stock valued at $549,223,000 after purchasing an additional 2,356,359 shares during the last quarter. Franklin Resources Inc. grew its position in Johnson & Johnson by 11.
4% during the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company’s stock worth $2,721,355,000 after purchasing an additional 1,729,281 shares during the period.
Finally, Holocene Advisors LP purchased a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $225,040,000. Institutional investors and hedge funds own 69.55% of the company’s stock.
Insider Buying and Selling at Johnson & Johnson In related news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.
22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220.
The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website . 0.
16% of the stock is owned by insiders. Johnson & Johnson Trading Up 0.7 % Johnson & Johnson Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th.
Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th.
This represents a $4.96 annualized dividend and a yield of 3.35%.
Johnson & Johnson’s dividend payout ratio is presently 71.78%. Wall Street Analyst Weigh In JNJ has been the topic of several analyst reports.
Bank of America dropped their target price on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating on the stock in a report on Friday, January 17th.
Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. StockNews.
com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 17th. Citigroup lowered their target price on shares of Johnson & Johnson from $185.00 to $175.
00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Finally, Guggenheim lifted their price target on Johnson & Johnson from $156.00 to $162.
00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $173.
27. Get Our Latest Research Report on Johnson & Johnson Johnson & Johnson Company Profile ( Free Report ) Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. Read More Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson ( NYSE:JNJ – Free Report ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter ..
